OBJECTIVE: Cannabis use increases the risk for psychosis, but psychotogenic effects of cannabis may be restricted to exposure during early adolescence. METHOD: Four hundred and seventy-two participants (aged 12-23 years), randomly selected from the general population in Trinidad, completed questionnaires on past and current cannabis use and psychotic symptoms (using the Community Assessment of Psychic Experiences). RESULTS: Cannabis use increased the risk of experiencing psychotic symptoms and this effect was conditional on early exposure, defined around the mean age of onset of cannabis use. Thus, exposure before but not after the age of 14 years predicted psychotic symptoms (respectively beta: 0.71, 95% CI 0.22; 1.19, P = 0.004 and beta: -0.11, 95% CI -0.57; 0.36, P = 0.66). The developmental effect of cannabis use was independent of use of other drugs or current use of cannabis. CONCLUSION: Early adolescence may be a critical period with regard to the psychotogenic effect of cannabis across geographical settings and ethnic groups.
OBJECTIVE: Cannabis use increases the risk for psychosis, but psychotogenic effects of cannabis may be restricted to exposure during early adolescence. METHOD: Four hundred and seventy-two participants (aged 12-23 years), randomly selected from the general population in Trinidad, completed questionnaires on past and current cannabis use and psychotic symptoms (using the Community Assessment of Psychic Experiences). RESULTS: Cannabis use increased the risk of experiencing psychotic symptoms and this effect was conditional on early exposure, defined around the mean age of onset of cannabis use. Thus, exposure before but not after the age of 14 years predicted psychotic symptoms (respectively beta: 0.71, 95% CI 0.22; 1.19, P = 0.004 and beta: -0.11, 95% CI -0.57; 0.36, P = 0.66). The developmental effect of cannabis use was independent of use of other drugs or current use of cannabis. CONCLUSION: Early adolescence may be a critical period with regard to the psychotogenic effect of cannabis across geographical settings and ethnic groups.
Authors: Hila Abush; Subroto Ghose; Erin A Van Enkevort; Brett A Clementz; Godfrey D Pearlson; John A Sweeney; Matcheri S Keshavan; Carol A Tamminga; Elena I Ivleva Journal: Psychiatry Res Neuroimaging Date: 2018-03-28 Impact factor: 2.376
Authors: Aine T Behan; Magdalena Hryniewiecka; Colm M P O'Tuathaigh; Anthony Kinsella; Mary Cannon; Maria Karayiorgou; Joseph A Gogos; John L Waddington; David R Cotter Journal: Neuropsychopharmacology Date: 2012-03-21 Impact factor: 7.853
Authors: Rebecca C Hanna; Alexandra Shalvoy; C Munro Cullum; Elena I Ivleva; Matcheri Keshavan; Godfrey Pearlson; S Kristian Hill; John A Sweeney; Carol A Tamminga; Subroto Ghose Journal: Schizophr Bull Date: 2016-03-31 Impact factor: 9.306
Authors: Marta Di Forti; Hannah Sallis; Fabio Allegri; Antonella Trotta; Laura Ferraro; Simona A Stilo; Arianna Marconi; Caterina La Cascia; Tiago Reis Marques; Carmine Pariante; Paola Dazzan; Valeria Mondelli; Alessandra Paparelli; Anna Kolliakou; Diana Prata; Fiona Gaughran; Anthony S David; Craig Morgan; Daniel Stahl; Mizanur Khondoker; James H MacCabe; Robin M Murray Journal: Schizophr Bull Date: 2013-12-17 Impact factor: 9.306